This funding supports basic, translational, and clinical research projects addressing chronic and delayed adverse sequelae of cancer therapies. Projects should elucidate mechanisms, clinically characterize sequelae, and develop interventions to prevent or reduce long-term effects. Emphasis is on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify clinical endpoints for future clinical trials.
Eligible applicants include a wide range of organizations such as for-profit entities (excluding small businesses), nonprofits, educational institutions, tribal governments, government agencies, and others including foreign organizations and regional bodies.
